VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - April 3, 2007) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") has completed the development of its T36® Microbicide Gel which is designed to prevent the spread of HIV and other Sexually Transmitted Infections ("STI's"). STI prevention is important because nearly 40 million people are now infected with HIV and 4 to 5 Million new HIV infections have been reported every year since 1999. The number of all new STI's, including HIV, is greater than 300 million per year.
